Mithra, a company dedicated to Women's Health, today announces it has entered into a license and supply agreement with Spirig Healthcare AG for the commercialization of its tibolone-based product Tibelia in Liechtenstein and Switzerland.
Developed by Mithra as the bioequivalent version of Livial, Tibelia is a complex oral formulation composed of tibolone, a synthetic steroid for use in hormone therapy. Tibolone relieves postmenopausal symptoms and prevents osteoporosis in postmenopausal women at high risk of future fractures who are intolerant to other medicinal products. To date, Tibelia is marketed in about 30 countries through existing license and supply agreements.
Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia in Liechtenstein and Switzerland, which has a tibolone market worth approximately EUR 1.5 million per year. Spirig HealthCare AG is a Swiss pharmaceutical company, subsidiary of the German group STADA Arzneimittel AG. It produces, markets and distributes more than 150 products, both high-quality generics and brands, to various healthcare professionals.
Francois Fornieri, CEO Mithra Women's Health, commented: 'We are pleased to have formed a partnership with Spirig Healthcare for the commercialization of Tibelia in Switzerland and Liechtenstein. With their large network and extensive services to doctors and pharmacists, they are the ideal partner to market our product in this region. This agreement is part of our strategy to continue to maximize the potential of our product around the world.'
About Mithra
Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle, a new era in oral contraception, PeriNesta, the first complete oral treatment targeting perimenopause and Donesta, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liege, Belgium. www.mithra.com
Contact:
Alexandra Deschner (IRO)
+32 490 58 35 23
investorrelations@mithra.com
Maud Vanderthommen (Press)
+32 473 58 61 04
press@mithra.com
Important information
The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
MITHRA PHARMACEUTICALS S.A. 
